|
Apr 16
|
Protagonist Therapeutics Reports Granting of Inducement Award
|
|
Apr 10
|
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
|
|
Mar 15
|
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?
|
|
Mar 13
|
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
|
|
Mar 12
|
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
|
|
Mar 11
|
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
|
|
Mar 11
|
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
|
|
Mar 11
|
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
|
|
Mar 11
|
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday
|
|
Mar 10
|
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
|
|
Mar 10
|
Sector Update: Health Care Stocks Decline Late Afternoon
|
|
Mar 10
|
Top Midday Gainers
|
|
Mar 10
|
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
|
|
Mar 3
|
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat
|
|
Mar 3
|
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
|
|
Mar 3
|
Takeda and Protagonist report topline outcomes from trial of rusfertide
|
|
Mar 3
|
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera
|
|
Mar 3
|
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
|
|
Feb 22
|
Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years
|
|
Feb 21
|
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
|